Skip to main content
. 2020 Jan 30;20:75. doi: 10.1186/s12885-020-6570-8

Fig. 2.

Fig. 2

a) Biochemical relapse-free rate; b) Biochemical relapse-free rate by risk group; c) Biochemical relapse-free rate by use of ADT in intermediate-risk group patients